OPKO HEALTH, INC. — Form SCHEDULE 13D
Filed August 7, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
▲ Likely positive
significance 68/100
What the filing says
OPKO Health, Inc. (market cap ~$539.5M) filed a Schedule 13D on August 7, 2026, disclosing acquisition of beneficial ownership in Cocrystal Pharma, Inc., a pharmaceutical company. The filing includes exhibits listing OPKO directors/officers, a joint filing agreement, and a power of attorney. Specific share count, percentage ownership, and transaction dollar amount are not disclosed in the provided filing header/index text.
Why this rating
Schedule 13D signals material ownership stake/deal activity. Specifics unavailable in header, but acquisition of another pharma firm is strategically significant relative to OPKO's $539.5M size. Requires document review for full quantification.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.